Peritoneal immune system in patients with advance epithelial ovarian cancer

International Reviews of Immunology

Volumn 30, Issue 2-3, 2011, Pages 87-101

  Wertel, Iwona ^a   Nowicka, Aldona ^a   Rogala, Ewelina ^a   Kotarski, Jan ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

dendritic cells; Ovarian cancer; peritoneal cavity; tumor infiltrating cells

Indexed keywords

ADVANCED CANCER; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL POPULATION; DENDRITIC CELL; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; MACROPHAGE; NONHUMAN; OVARY CANCER; PERITONEAL CAVITY; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH17 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ASCITIC FLUID; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNE SYSTEM; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 79955820929     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2011.569902     Document Type: Article

References (145)

1. Gandawidjaja L, Hau T. Anatomic, physiologic, bacteriologic and immunologic aspects of peritonitis. Acta Chir Belg 1997;97:163-167. (Pubitemid 127520646)
2. Chechlinska M, Kaminska J, Markowska J, Stefen J. Peritoneal fuid cytokines and the diferential diagnosis of benign and malignant ovarian tumors and residua/recurrent diseaseexamination. Int J Biol Markers 2007;22:172-180. (Pubitemid 350081625)
3. Ho HN, Wu MY, Yang YS, Peritoneal cellular immunity and endometriosis. Am J Reprod Immunol 1997;38:400-412.
4. Gerber SA, Rybalko, VY, Bigelow CE, et al. Preferentialattachment of peritoneal tumor metastases to omental immune aggregates and possible role ofa unique vascular microenvironment in metastatic survival and growth. Am J Pathol 2006;169:1739-1752. (Pubitemid 351182005)
5. Ionodes CG, Platsoucas CD, Rashed S, et al. Tumor cytolysis by lymphocytes infltrating ovarian malignant ascites. Cancer Res 1991;51:4257-4265.
6. Melichar B, Freedman RS. Immunology of the peritoneal cavity: Relevance for host-tumor relation. Int J Gynecol Cancer 2002;12:3-17. (Pubitemid 34202943)
7. Krist LF, Eestermans IL, Steenbergen JJ, et al. Cellular composition of milky spots in the human greater omentum: An immunochemical and ultrastructural study. Anat Rec 1995;241:163-174.
8. Sorensen EW, Gerber SA, Sedlacek AL, et al. Omental immune aggregates and tumor metastatis within the peritoneal cavity. Immunol Res 2009;45:185-194.
9. Beelen RH. The greater omentum: Physiology and immunological concepts. Neth J Surg 1991;43:145-149.
10. Kearney JF, Bartels J, Hamilton AM, et al. Development and function of the early B cell reperoire. Int Rev Immunol 1992;8:247-257.
11. Gabrilovich DI, Bronte V, Chen SH, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007;67:425, author reply 426. (Pubitemid 46142802)
12. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949. (Pubitemid 39273735)
13. Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of T17 cells in the human tumor environments. Blood 2009;114:1141-1149.
14. Melichar B, Touskova M, Tosner J, Kopecky O. Tephenotype of ascitic fuid lymphocytes in patients with ovarian carcinoma and other primaries. Onkologie 2001;24:156-160. (Pubitemid 32449012)
15. Wertel I, Polak G, Bednarek W, et al. Dendritic cell subsets in the peritoneal fuid and peripheral blood of women sufering from ovarian cancer. Cytometry B Clin Cytom 2008;74:251-258. (Pubitemid 352007323)
16. Zou W, Machelon V, Coulomb-L'Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7:1339-1346. (Pubitemid 34007939)
17. Bamias A, Tsiatas ML, Kafantari E, et al. Signifcant diferences of lymphocytes isolated from as-cites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Gynecol Oncol 2007;106:75-81. (Pubitemid 46898574)
18. Dong HP, Elstrand MB, Holth A, et al. NK-and B-cell infltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 2006;125:451-458. (Pubitemid 43327717)
19. Santin AD, Hermonat PL, Ravaggi A, et al. Phenotypic and functional analysis of tumor-infltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fuid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest 2001;51:254-261. (Pubitemid 32620125)
20. + regulatory T cell is increased in the patients with ovarian carcinoma. Cancer Invest 2005;23:399-403. (Pubitemid 41324357)
21. Kryczek I, Wei S, Zou L, et al. Cutting edge: T17 and regulatory T cell dynamics and the regulation by IL-12 in the tumor microenvironment. J Immuno 2007;178:6730-6733. (Pubitemid 46847396)
22. Miyahara Y, Odunsi K, Chen W, et al. Generation and regulation of human CD4+ IL-17 producing T cells in ovarian cancer. PNAS 2008;105:15505-15510.
23. Coussens LM, Werb Z. Infammation and cancer. Nature 2002;420: 860-867.
24. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002;13:143-154. (Pubitemid 34229389)
25. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-296.
26. Avigan D. Dendritic cells: Development, function and potential use for cancer immunotherapy. Blood Rev 1999;13:51-64. (Pubitemid 29178531)
27. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811. (Pubitemid 30365397)
28. Robinson SP, Patterson S, English N, et al. Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol 1999;29:2769-2778. (Pubitemid 30099001)
29. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004;5:1219-1226. (Pubitemid 41057736)
30. Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: Tree markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000;165:6037-6046.
31. O'Doherty U, Peng M, Gezelter S, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994;82:487-493. (Pubitemid 24251635)
32. Betjes MGH, Tuk CW, Struijk DG, et al. Antigen-presenting capacity of macrophages and dendritic cells in the peritoneal cavity of patients treated with peritoneal dialysis. Clin Exp Immunol 1993;94:377-384. (Pubitemid 23337843)
33. Betjes MGH, Haks MC, Tuck CW, Beelen RH. Monoclonal antibody EBM11 (anti-CD68) discriminates between dendritic cells and macrophages after short-term culture. Immunobiol 1991;183:79-87.
34. Kubicka U, Olszewski WL, Tarnowski W, et al. Normal human immune peritoneal cells: subpopu-lations and functional characteristics. Scand J Immunol 1996;44:157-163. (Pubitemid 26246735)
35. Eisenthal A, Polyvkin N, Bramante-Schreiber L, et al. Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer. Hum Pathol 2001;32:803-807. (Pubitemid 32803980)
36. + cells with the phenotype of undiferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin Cancer Res 1998;4:799-809. (Pubitemid 28193581)
37. Curiel TJ, Cheng P, Mottram P, et al. Dendritic cells subsets diferentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004;64:5535-5538. (Pubitemid 39095544)
38. Sowter HM, Corps AN, Evans AL, et al. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 1997;77:607-614. (Pubitemid 28018781)
39. Paley PJ, Staskus KA, Gebhard K, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997;80:98-106. (Pubitemid 27270925)
40. Santin AD, Hermonat PL, Ravaggi A, et al. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol 1999;20:177-181. (Pubitemid 29286483)
41. Berger S, Siegert A, Denkert C, et al. Interleukin-10 in serous ovarian carcinoma cell lines. Cancer Immunol Immunother 2001;50:328-333. (Pubitemid 32757465)
42. Zhou J, Ye F, Chen H, et al. The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res 2007;35:290-300. (Pubitemid 46971349)
43. Rabinovich A, Medina L, Piura B, Huleihel M. Expression of IL-10 in human normal and cancerous ovarian tissues and cells. Eur Cytokine Netw 2010;21:122-128.
44. Berchuck A, Rodriguez G, Olt G, et al. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. Am J Obstet Gynecol 1992;166:676-684.
45. Toutirais O, Chartier P, Dubois D, Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw 2003;14:246-255. (Pubitemid 38122233)
46. Burger RA, Grosen EA, Ioli GR, et al. Spontaneous release of interleukin-6 by primary cultures of lymphoid and tumor cell populations purifed from human ovarian carcinoma. J Interferon Cy-tokine Res 1995;15:255-260.
47. Ofner FA, Obrist P, Stadlmann S, et al. IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine 1995;7:542-547.
48. Bennaceur K, Chapman JA, Touraine J, Portoukalian J. Immunosuppressive networks in the tumor environment and their efect in dendritic cells. Biochem et Biophysica Acta 2009;1795:16-24.
49. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213-1222.
50. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-Specific inhibition of efector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-238. (Pubitemid 32524454)
51. Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001;2:1010-1017. (Pubitemid 33069495)
52. +regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003;198:235-247. (Pubitemid 37009740)
53. Verhasselt V, Vosters O, Beuneu C, et al. Induction of FOXP3-expressing regulatory CD4pos T cells by human mature autologous dendritic cells. Eur J Immunol 2004;34:762-772. (Pubitemid 39255924)
54. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257.
55. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated anti-tumor immunity. Nat Med 2003;9:562-567. (Pubitemid 36597102)
56. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002;8:793-800.
57. ZouW, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-477.
58. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007;104:3360-3365. (Pubitemid 46364164)
59. Matsui T, Connolly JE, Michnevitz M, et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 2009;182:6815-6823.
60. Liu YJ. IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275-306.
61. Steinman RM. Dendritic cells: Understanding immunogenicity. Eur J Immunol 2007;37:53-60.
62. Hadeiba H, Sato T, Habtezion A, et al. CCR9 expression defnes tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease. Nat Immunol 2008;9:1253-1260.
63. Matta BM, Castellaneta A, Tomson AW. Tolerogenic plasmacytoid DC. Eur J Immunol 2010;40:2667-2676.
64. Gilliet M, Liu YJ. Human plasmacytoid-derived dendritic cells and the induction of T-regulatory cells. Hum Immunol 2002;63:1149-1155. (Pubitemid 36025989)
65. Wei S, Kryczek I, Zou L, et al. Plasmacytoid dendritic cells induce CD8 +regulatory T cells in human ovarian carcinoma. Cancer Res 2005;65:5020-5026. (Pubitemid 40827308)
66. Zabel BA, Silverio AM, Butcher EC. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J Immunol 2005;174:244-251. (Pubitemid 40007410)
67. Melichar B, Savary CA, Patenia R, et al. Phenotype and antitumor activity of ascitic fuid monocytes in patients with ovarian carcinoma. Int J Gynecol Cancer 2003;13:435-443. (Pubitemid 38220661)
68. Gordon IO, Freedman RS. Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res 2006;12:1515-1524.
69. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-78. (Pubitemid 38082155)
70. Hibbs Jr., JB, Taintor RR, Vavrin Z. Macrophage cytotoxicity: Role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 1987;235:473-476. (Pubitemid 17009584)
71. Dong Z, Yoneda J, Kumar R, Fidler IJ. Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor. J Exp Med 1998;188:755-763. (Pubitemid 28387938)
72. Loercher AE, Nash MA, Kavanagh JJ, et al. Identifcation of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cy-tokine protein expression and proliferation of autologous T cells. J Immunol 1999;163:6251-6260.
73. Young MR, Newby M, Wepsic HT. Hematopoiesis and suppressorbone marrow cells in micebearing large metastatic Lewis lung carcinoma tumors. Cancer Res 1998;47:100-105.
74. Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifes a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006;203;871-888.
75. Kryczek I, Wei S, Zhu G, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007;67:8900-8905. (Pubitemid 47437467)
76. Yigit R, Massuger LFAG, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvi-ronment to escape immune elimination. Gyn Oncol 2010;117:366-372.
77. Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human T17 cells. J Exp Med 2007;20:1849-1861. (Pubitemid 47240944)
78. Zhang L, Conejo-Garcia JR, Katsaros, D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213. (Pubitemid 36077915)
79. Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 2008;222:101-116. (Pubitemid 351430376)
80. Rabinowich H, Suminami Y, Reichert TE, et al. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 1996;68:276-284. (Pubitemid 26384127)
81. Lockhart DC, Chan Ak, Mak S, et al. Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. Surgery 2001;129:749-756. (Pubitemid 32493679)
82. +tumor-infltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008;108:415-420. (Pubitemid 351174290)
83. Raspollini MR, Castiglione F, Degl'Innocenti DR, et al. Tumour-infltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 2005;16;590-596. (Pubitemid 40613325)
84. + tumor-inftrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci 2005;102:18538-18543. (Pubitemid 43011261)
85. Barnett B, Kryczek I, Cheng P, et al. Regulatory T cells in ovarian cancer: Biology and therapeutic potential. Am J Reprod Immunol 2005;54:369-377. (Pubitemid 41748714)
86. Weaver CT, Harrington LE, Mangan PR, et al. T17 an efector CD4 T cell lineage with regulatory T cell ties. Immunity 2006;24:677-688. (Pubitemid 43867371)
87. Harrington LE, Mangan PR, Weaver CT. Expanding the efector CD4 T-cell repertoire: The T17 lineage. Curr Opin Immunol 2006;18:349-356.
88. Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the difer-entiation program of proinfammatory IL-17+ T helper cells. Cell 2006;126:1121-1133. (Pubitemid 44380299)
89. Yang XO, Pappu BP, Nurieva R, et al. T helper lineage diferentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008;28:29-39.
90. Egwuagu CE. STAT3 in CD4+ T helper cells diferentiation and infammatory diseases. Cytokine 2009;47:149-156.
91. Chen Q., Yang W., Gupta S., et al. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity.2008;29:899-911.
92. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profle and function of human inter-leukin 17-producing helper T cells. Nat Immunol 2007;8:950-957. (Pubitemid 47300009)
93. Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specifcity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8:942-949.
94. Kato IT, Furumoto H, Ogura T, et al. Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun 2001;282:735-738. (Pubitemid 32924619)
95. Leveque L, Deknuydt F, Bioley G, et al. Interleukin-2 mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinfammatory interleukin 17-producing helper T cells. J Immunother 2009;32:101-108.
96. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101;2620-2627. (Pubitemid 36857622)
97. Kolls JK, Linden A. Interleukin-17 family members and infammation. Immunity 2004;21:467-476.
98. Charles KA, Kulbe H, Soper R, et al. The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009;119:3011-3023.
99. Benchetrit F, Ciree A, Vives V, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002;99:2114-2121. (Pubitemid 34525496)
100. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-4772. (Pubitemid 32691889)
101. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3:253-257. (Pubitemid 37323210)
102. Curiel JT. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167-1174.
103. Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cell-Specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11,8326-8331. (Pubitemid 41746944)
104. Lefers N, Gooden MJM, deJong RA, et al. Prognostic signifcance of tumor-infltrating T-lymphocytes in primary and matastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009;58:449-459.
105. Serafni P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biol 2006;16:53-65. (Pubitemid 43139709)
106. Youn JI, Nagaraj S, Collazo M,GabrilovichDI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008;181:5791-5802.
107. Movahedi K, Guilliams M, Bossche J. Identifcation of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008;111:4233-4244.
108. Conejo-Garcia JR, Buckanovich RJ, Benencia F, et al. Vascular leukocytes contribute to tumor vas-cularization. Blood 2005;105:679-681. (Pubitemid 40070752)
109. Balint K, Conejo-Garcia JR, Buckanovich R, Coukos G. Role of vascular leukocytes in ovarian cancer neovascularisation. Adv Exp Med Biol 2008;622:273-280.
110. Coucos G., J.R. Conejo-Garcia JR, Buckanovich R., Benencia F. Vascular leukocytes: A population with angiogenic and immunosuppressive properties highly represented in ovarian cancer. Adv Exp Med Biol 2007;590:185-193.
111. Bak SP, Walters JJ, akeya M., et al. Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer Res 2007;67:4783-4789. (Pubitemid 46910186)
112. Peter S, Bak G, Hart K, Berwin B. Ovarian tumor-inducedTcell suppression is alleviated by vascular leukocyte depletion. Translational Oncol.2009;2:291-299.
113. Nishizuka Y., Sakakura T., Taguchi O., Mechanism of ovarian tumorigenesis in miceafter neonatal thymectomy in mice. Science 1969;166:753-755.
114. Wei S, Kryczek I, Zou L, et al. Novel tumor immunotherapy: Targeting dysfunctional antigen presenting cells. Discov Med 2005;5:489-492.
115. Tringler B, Liu W, Corral L, et al. B7-H4 overexpression in ovarian tumors. Gynecol Oncol 2006;100:44-52. (Pubitemid 41815048)
116. Zang X, Sullivan PS, Soslow RA, et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 2010;23:1104-1112.
117. Simon I, Zhuo S, Corral L, et al. B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 2006;66:1570-1575. (Pubitemid 43259939)
118. Cannon MJ, O'Brien TJ. Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ter 2009;9:677-688.
119. Scotton CJ, Wilson JL, Milliken D, et al. Epithelial cancer cell migration: A role for chemokine receptors? Cancer Res 2001;61:4961-4965. (Pubitemid 32681518)
120. Jiang YP, Wu XH, Shi B, et al. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: An independent prognostic factor for tumor progression. Gynecol Oncol 2006;103:226-323.
121. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-274. (Pubitemid 40488632)
122. Kajiyama H, Shibata K, Terauchi M, et al. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 2008;122:91-99. (Pubitemid 350209982)
123. Okamoto A, Nikaido T, Ochiai K, et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profles of serous ovarian cancer cells. Clin Cancer Res 2005;11:6030-6039. (Pubitemid 41170335)
124. Takao M, Okamoto A, Nikaido T, et al. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 2007;17:1333-1339.
125. Munn DH, Sharma MD,Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002;297:1867-1870. (Pubitemid 35024345)
126. Kryczek I, Lange A, Mottram P, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005;65:465-472.
127. Kryczek I, Wei S, Keller E, et al. Stroma-derived factor (SDF-1/CXCL12) and human tumor patho-genesis. Am J Physiol Cell Physiol 2007;292:C987-C995. (Pubitemid 46440396)
128. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-1103. (Pubitemid 26338628)
129. Mimura K, Kono K, Takahashi A, et al. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother 2007;56:761-770. (Pubitemid 46723581)
130. Dworak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cy-tokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-4380.
131. Gabrilovich DI, Ishida T, Nadaf S, et al. Antibodies to vascularendothelialgrowthfactor enhance the efcacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999;5:2963-2970. (Pubitemid 29493976)
132. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9:5721-5728. (Pubitemid 37499496)
133. Hu L, Hofmann J, Holash J, et al. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005;11:6966-6971. (Pubitemid 41428755)
134. Rodriguez GC, Haisley C, Hurteau J, et al. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol 2001;80:245-253. (Pubitemid 32158466)
135. +CD25-T cells through secreting TGF-β. Cancer Letters 2007;253:144-153. (Pubitemid 46874736)
136. Pepper MS. Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 1997;8:21-43. (Pubitemid 27214687)
137. Rodŕguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives. Immunol Rev 2008;222:180-191. (Pubitemid 351430370)
138. Conejo-Garcia JR, Benencia F, Courreges MC, et al. Tumor-infltraiting dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the infuence of Vegf-A. Nat Med 2004;10:950-958. (Pubitemid 39273736)
139. Huarte E, Cubillos-Ruiz JR, Nesbeth YC, et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008;68:7684-7691.
140. Jarnicki AG, Conroy H, Brereton C, et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efcacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008;180:3797-3806.
141. Chekmasova AA, Brentjens RJ. Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer. Discov Med 2010;9:62-70.
142. Liu B, Nash J, Runowicz C, et al. Ovarian cancer immunotherapy: Opportunities, progresses and challenges. J Hematol Oncol 2010;3:7-11.
143. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modifed T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-6115. (Pubitemid 44703776)
144. Barber A, Zhang T, DeMars LR, et al. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res 2007;67:5003-5008. (Pubitemid 46910210)
145. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 2009;106:3360-3365.